DOCSLIB.ORG

United States Patent (19) 11) Patent Number: 4,704,119 Shaw Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11) Patent Number: 4,704,119 Shaw Et Al United States Patent (19) 11) Patent Number: 4,704,119 Shaw et al. 45 Date of Patent: Nov. 3, 1987 54 METHOD COMPRISING TRANSDERMAL 4,060,084 1 1/1977 Chandrasekaran et al......... 128/260 AND BUCCAL TREATMENT OF ANGINA 4,262,003 4/1981 Urquhart et al. ................... 128/260 4,286,692 9/1981 Chandrasekaran ..... ... 128/260 75 Inventors: Jane Shaw, Atherton; Robert M. 4,329,333 5/1982 Barr....................................... 424/19 Gale, Mountain View, both of Calif. 4,350,785 9/1982 Habib .................................... 524/55 73) Assignee: ALZA Corporation, Palo Alto, Calif. FOREIGN PATENT DOCUMENTS 21 Appl. No.: 932,440 0013606 4/1980 European Pat. Off. 22 Filed: Nov. 19, 1986 OTHER PUBLICATIONS Boehm, ANGEWANDTE CHEMIE vol. 5, pp. 533, Related U.S. Application Data 538-541, 1966. 63 Continuation of Ser. No. 463,593, Feb. 3, 1983, Pat. Cabot, Advertisements, pp. 4, 9, 12 and 18, 1979. No. 4,650,484, which is a continuation of Ser. No. Parkyns, Cata. Proc. Int. Congr. 5th, vol. 12, pp. 255 & 285,862, Jul 22, 1981, abandoned. 261, 1973. 51) Int. Cl." ........................... A61K9/00; A61J 3/00; Goodman, The Pharmacological Basis of Therapeutics, AON 25/26 4th Ed., p. 752, 1970. I52) U.S.C. ..................................... 604/897; 604/304 Burch, Am. Heart J., p. 842, 1966. 58) Field of Search ................................ 604/304-307, Csaky, Handbook of Pharmacology, 6th Ed., pp. 604/896, 897; 128/156 241-243, 1979. 56) References Cited Banes, J. Pharm. Sci., vol. 57, pp. 893-894, 1968. Merck, The Merck Index, p. 965, 1968. U.S. PATENT DOCUMENTS Pauling, The Nature of The Chemical Bond, p. 495, 1960. 2,896,819 7/1975 Zaffaroni ............................ 128/130 3,028,307 4/1962 Ninger ... ... 67/82 Primary Examiner-Stephen C. Pellegrino 3,063,900 1 1/1962 Winsor ... 167/65 Assistant Examiner-Jerome R. Smith, Jr. 3,096,242 7/1963 Young ... ... 167/65 Attorney, Agent, or Firm-Paul L. Sabatine; Edward L. 3,428,723 2/1969 Lowey ... ... 424/14 Mandell; Steven F. Stone A. 3,742,951 7/1973 Zaffaroni .... 28/268 3,789,119 1/1974 Fusari et al. .......................... 424/78 57 ABSTRACT 3,797,494 3/1974 Zaffaroni ... ... 128/268 A method is disclosed for treating an ischemic condi 3,921,636 11/1975 Zaffaroni ... ... 28/260 3,948,262 4/1976 Zaffaroni .... ... 128A260 tion. The method comprises coadministering topically 3,980,084 9/1976 Kross ......... ... 128/263 and internally a vasodilator to a patient having the con 3,996,634 12/1976 Zaffaroni ... 28A268 dition for treating said condition. 4,014,335 3/1977 Arnold ................................ 28/260 4,031,894 6/1977 Urquhart et al. ................... 128/268 3 Claims, 3 Drawing Figures U.S. Patent Nov. 3, 1987 4,704,119 FG, 12 N 3 4 1121212121212124 29 3. 30 SSGN / N sS Ess3 4,704,119 1. 2 flicted with same by administering a vasodilator drug or METHOD COMPRISING TRANSIDERMAL AND different vasodilator drugs topically and simultaneously BUCCAL TREATMENT OF ANGINA internally for obtaining clinical and therapeutic efficacy in treating angina pectoris. CROSS-REFERENCE TO RELATED 5 Yet another object of this invention is to provide a APPLICATIONS method for lessening the incidence of anginal attacks by This a continuation of U.S. patent application Ser. administering at least one vasodilator drug in a thera No. 06/463,593 filed on Feb. 3, 1983 now U.S. Pat. No. peutically effective amount topically and internally for 4,650,484, which application Ser. No. 06/463,593 is a producing the intended result. continuation of U.S. patent application Ser. No. 10 Other objects features and advantages of this inven 06/285,862 filed on July 22, 1981 now abandoned. tion will be more apparent to those skilled in the art These applications are incorporated herein by reference from the detailed description of the invention, and the and benefit is claimed of their filing dates. These appli accompanying claims. cations are assigned to ALZA Corporation of Palo 15 DETAILED DESCRIPTION OF THE Alto, California. INVENTION FIELD OF THE INVENTION In accordance with the practice of the invention, This invention pertains to a method for the manage there is provided a method comprising administering a ment of ischemic conditions including angina pectoris vasodilator drug in a therapeutically effective and bene by administering topically and internally a vasodilator ficial amount both topically and internally to a human drug to a symptomatic patient. patient over time. The method comprises coadminister ing the vasodilator simultaneously topically and inter BACKGROUND OF THE INVENTION nally, topically then internally, internally then topically, Vasodilator drugs are the mainstay in the symptom multiple administrations topically and internally, multi atic treatment of ischemic conditions including angina 25 ple administrations internally and topically, and the like. pectoris. Patients afflicted with these conditions, espe The term topically as used herein, denotes adminis cially angina pectoris, may require almost immediate tering to the skin of a patient in need of a vasodilator therapeutic response to a vasodilator drug for relief drug, the drug for percutaneous passage of the vasodi from pain, and in some instances fright, or patients with angina pectoris may require a continuous therapeutic 30 lator into the systemic circulation of the patient. The response to a vasodilator drug to decrease the fre skin sites include anatomic regions for transdermally quency and severity of attacks. Consequently, vasodi administering the drug as represented by the forearm, lator drugs frequently are administered sublingually abdomen, chest, back, buttock, mastoidal area and the because this method provides a rapid onset of therapeu like. The vasodilator is administered to the skin by plac tic effect and accompanying immediate relief of symp 35 ing on the skin a bandage that administers the vasodi toms; also vasodilator drugs are frequently administered lator, and which bandage is designed, shaped, sized, and orally because this method provides a longer duration adapted for easy placement and comfortable retention of action for alleviating clinical symptoms and can pro on the skin. vide prophylactic benefit. The term internally as used herein, denotes adminis While the above methods of administration provide 40 tering the vasodilator orally into the gastrointestinal needed benefits, there are disadvantages associated tract, administering the vasodilator into the mouth such therewith. For example, sublingually administered vas as buccally to the inner surface of the cheeks, and sub odilator drugs have a brief duration of action making it lingually beneath the tongue. The vasodilator can be necessary for some patients to take many doses, and administered internally in pharmaceutical formulations orally administered vasodilator drugs often are used in 45 expressed as tablet, sustained release, pellet, capsule, high doses, they are erratically absorbed into the sys solution, suspension, and the like. temic circulation, and do not provide continuous ther The phrase vasodilator drug, and the term vasodi apy. lator as used herein denotes vasodilators including ni trites, nitrates and their esters, such as their esters of OBJECTS OF THE INVENTION 50 sugars and polyols. The vasodilators generically possess Accordingly, it is an immediate object of this inven a member selected from the group consisting of ONO, tion to provide both a novel and useful method for and ONO2. The vasodilators include amyl nitrite, ethyl treating ischemic conditions including angina pectoris, nitrite, glyceryl trinitrate, also known as nitroglycerin, which method overcomes the disadvantages known to nitroglycerin absorbed on lactose such as 1 to 30% the prior art. 55 nitroglycerin on 99 to 70% lactose, preferrably 10% Another object of the invention is to provide a nitroglycerin and 90% beta-lactose, or optionally on method for treating ischemic conditions including an alpha-lactose, octyl nitrite, sodium nitrite, clonitrate, gina pectoris, which method comprises a combination erythrityl tetranitrate, isosorbide dinitrate, mannitol of administering a vasodilator drug topically and inter hexanitrate, pentaerythritol tetranitrate, penetrinitol, nally to a patient in need of such treatment. 60 triethanolamine trinitrate, trolnitrate phosphate (trieth Another object of the invention is to provide a anolamine trinitrate diphosphate), propatylnitrate, and method for treating ischemic conditions including in the like. tractable angina pectoris which method comprises ad The expression ischemic conditions as used herein ministering a vasodilator drug topically and concomi generically denotes coriditions that respond to vasodi tantly internally to produce clinically satisfactory re 65 lator therapy through hemodynamic response and the sults. like. The condition includes vasodilators used to relieve Yet still another object of this invention is to provide pain in the treatment of its most common clinical ex a method for treating angina pectoris in a human af. pression angina pectoris, as a prophylactic for the pre 4,704,119 3 4 vention of angina pectoris and in hypertension, for the Reservoir 22 is formed of a gelled fluid 26 having a low relaxation of the involuntary muscles of the blood ves to high viscosity. Reservoir 22 is preferrably made as a sels mainly the arteries and arterioles, for increasing continuous phase and it contains rheology agent 27 with oxygenation from vasodilation, mainly for increasing vasodilator dispersed throughout the reservoir. In ban the supply of oxygen to the heart, for improving exer 5 dage 20, outer edges 28 of backing member 21 can over cise performance, in the pharmaco-prevention of coro lay edges 19 of reservoir 22 and in this manufacture they nary disease, for increasing the circulation in the vascu will join edges 29 of membrane 24 in fluid tight arrange lar bed for warming cold fingers and toes and for treat ment. The sealed reservoir is made by pressure sealing, ing frostbite. The vasodilators and their uses are known fusion, adhesion, or through an adhesive applied to the in Cutting's Handbook of Pharmacology, Sixth Edition, O edges of contacting members.
Load more

Recommended publications
  • Comparison of the Antiischaemic and Antianginal Effects of Nicorandil and Amlodipine in Patients with Symptomatic Stable Angina Pectoris: the SWAN Study
    Journal of Clinical and Basic Cardiology An Independent International Scientific Journal Journal of Clinical and Basic Cardiology 1999; 2 (2), 213-217 Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study The SWAN Study Group Homepage: www.kup.at/jcbc Online Data Base Search for Authors and Keywords Indexed in Chemical Abstracts EMBASE/Excerpta Medica Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · A-3003 Gablitz/Austria ORIGINAL PAPERS, CLINICAL The SWAN study J Clin Basic Cardiol 1999; 2: 213 Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study The SWAN Study Group1 This multicentre, double-blind, randomised study compared the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris. Nicorandil is a new coronary and balanced peripheral vasodilating agent that operates through two mechanisms of action: activation of ATP-dependent K-channels and stimulation of guanylate cyclase. A total of 121 patients with symptomatic stable angina pectoris were randomised to receive nicorandil 10 mg twice daily (bd) or amlodipine 5 mg once daily (od) for 8 weeks (optional dosage increase after 2-4 weeks to 20 mg bd and 10 mg od, respec- tively). Symptom-limited exercise tolerance tests were performed at baseline, and after 2 and 8 weeks treatment, respectively. In addition, the number of anginal attacks, nitroglycerin (NTG) usage, blood pressure (BP), heart rate (HR) and adverse events were recorded, and a subjective assessment of quality of life performed.
    [Show full text]
  • Tolerance and Resistance to Organic Nitrates in Human Blood Vessels
    \ö-\2- Tolerance and Resistance to Organic Nitrates in Human Blood Vessels Peter Radford Sage MBBS, FRACP Thesis submit.ted for the degree of Doctor of Philosuphy Department of Medicine University of Adelaide and Cardiology Unit The Queen Elizabeth Hospital I Table of Gontents Summary vii Declaration x Acknowledgments xi Abbreviations xil Publications xtil. l.INTRODUCTION l.L Historical Perspective I i.2 Chemical Structure and Available Preparations I 1.3 Cellular/biochemical mechanism of action 2 1.3.1 What is the pharmacologically active moiety? 3 1.3.2 How i.s the active moiety formed? i 4 1.3.3 Which enzyme system(s) is involved in nitrate bioconversi<¡n? 5 1.3.4 What is the role of sulphydryl groups in nitrate action? 9 1.3.5 Cellular mechanism of action after release of the active moiety 11 1.4 Pharmacokinetics t2 1.5 Pharmacological Effects r5 1.5.1 Vascular effects 15 l.5.2Platelet Effects t7 1.5.3 Myocardial effects 18 1.6 Clinical Efhcacy 18 1.6.1 Stable angina pectoris 18 1.6.2 Unstable angina pectoris 2t 1.6.3 Acute myocardial infarction 2l 1.6.4 Congestive Heart Failure 23 ll 1.6.5 Other 24 1.7 Relationship with the endothelium and EDRF 24 1.7.1 EDRF and the endothelium 24 1.7.2 Nitrate-endothelium interactions 2l 1.8 Factors limiting nitrate efficacy' Nitrate tolerance 28 1.8.1 Historical notes 28 1.8.2 Clinical evidence for nitrate tolerance 29 1.8.3 True/cellular nitrate tolerance 31 1.8.3.1 Previous studies 31 | .8.3.2 Postulated mechanisms of true/cellular tolerance JJ 1.8.3.2.1 The "sulphydryl depletion" hypothesis JJ 1.8.3.2.2 Desensitization of guanylate cyclase 35 1 8.i.?..3 Impaired nitrate bioconversion 36 1.8.3.2.4'Ihe "superoxide hypothesis" 38 I.8.3.2.5 Other possible mechanisms 42 1.8.4 Pseudotolerance ; 42 1.8.4.
    [Show full text]
  • Current Status of Local Penile Therapy
    International Journal of Impotence Research (2002) 14, Suppl 1, S70–S81 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir Current status of local penile therapy F Montorsi1*, A Salonia1, M Zanoni1, P Pompa1, A Cestari1, G Guazzoni1, L Barbieri1 and P Rigatti1 1Department of Urology, University Vita e Salute – San Raffaele, Milan, Italy Guidelines for management of patients with erectile dysfunction indicate that intraurethral and intracavernosal injection therapies represent the second-line treatment available. Efficacy of intracavernosal injections seems superior to that of the intraurethral delivery of drugs, and this may explain the current larger diffusion of the former modality. Safety of these two therapeutic options is well established; however, the attrition rate with these approaches is significant and most patients eventually drop out of treatment. Newer agents with better efficacy-safety profiles and using user-friendly devices for drug administration may potentially increase the long-term satisfaction rate achieved with these therapies. Topical therapy has the potential to become a first- line treatment for erectile dysfunction because it acts locally and is easy to use. At this time, however, the crossing of the barrier caused by the penile skin and tunica albuginea has limited the efficacy of the drugs used. International Journal of Impotence Research (2002) 14, Suppl 1, S70–S81. DOI: 10.1038= sj=ijir=3900808 Keywords: erectile dysfunction; local penile therapy; topical therapy; alprostadil Introduction second patient category might be represented by those requesting a fast response, which cannot be obtained by sildenafil; however, sublingual apomor- Management of patients with erectile dysfunction phine is characterized by a fast onset of action and has been recently grouped into three different may represent an effective solution for these 1 levels.
    [Show full text]
  • 21 CFR Ch. I (4–1–05 Edition)
    § 250.102 21 CFR Ch. I (4–1–05 Edition) health, inhalers containing meth- any use other than management of an- amphetamine or methamphetamine gina pectoris, or that is represented to salts (d-desoxyephedrine, or dl-desoxy- be efficacious for any other purpose by ephedrine, or their salts), as well as reason of its containing such drug, will amphetamine inhalers should be re- be regarded by the Food and Drug Ad- stricted to prescription sale and should ministration as misbranded and subject be labeled with the statement ‘‘Rx to regulatory proceedings, unless such only.’’ recommendations are covered by the approval of a new-drug application [40 FR 14033, Mar. 27, 1975, as amended at 67 FR 4906, Feb. 1, 2002] based on a showing of safety and effec- tiveness. § 250.102 Drug preparations intended (d) Any such drug in long-acting dos- for human use containing certain age form is regarded as a new drug that ‘‘coronary vasodilators’’. requires an approved new-drug applica- (a)(1) The Food and Drug Administra- tion before marketing. tion finds that the following ‘‘coronary (e) Any of the drugs listed in para- vasodilators’’ are extensively regarded graph (a)(2) of this section is regarded by physicians as safe and useful as em- as a new drug that requires an ap- ployed under medical supervision for proved new-drug application. Articles the management of angina pectoris in for which new-drug approvals are now some patients: in effect should be covered by supple- mental new-drug applications as nec- Amyl nitrite. essary to provide for labeling revisions Erythrityl tetranitrate.
    [Show full text]
  • Reverse Auction: a Potential Strategy for Reduction of Pharmacological Therapy Cost
    Original Article Reverse Auction: A Potential Strategy for Reduction of Pharmacological Therapy Cost Sara Michelly Gonçalves Brandão, Victor Sarli Issa, Silvia Moreira Ayub-Ferreira, Samantha Storer, Bianca Gigliotti Gonçalves, Valter Garcia Santos, Nelson Carvas Junior, Guilherme Veiga Guimarães, Edimar Alcides Bocchi Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, SP - Brazil Abstract Background: Polypharmacy is a significant economic burden. Objective: We tested whether using reverse auction (RA) as compared with commercial pharmacy (CP) to purchase medicine results in lower pharmaceutical costs for heart failure (HF) and heart transplantation (HT) outpatients. Methods: We compared the costs via RA versus CP in 808 HF and 147 HT patients followed from 2009 through 2011, and evaluated the influence of clinical and demographic variables on cost. Results: The monthly cost per patient for HF drugs acquired via RA was $10.15 (IQ 3.51-40.22) versus $161.76 (IQ 86.05-340.15) via CP; for HT, those costs were $393.08 (IQ 124.74-774.76) and $1,207.70 (IQ 604.48-2,499.97), respectively. Conclusions: RA may reduce the cost of prescription drugs for HF and HT, potentially making HF treatment more accessible. Clinical characteristics can influence the cost and benefits of RA. RA may be a new health policy strategy to reduce costs of prescribed medications for HF and HT patients, reducing the economic burden of treatment.(Arq Bras Cardiol. 2015; 105(3):265-275) Keywords: Heart Failure; Pharmaceutical Preparations / economics; Competitive Bidding / economics; Budgets; Cost Savings; Heart Transplantation. Introduction Health resources are scarce, but the needs are unlimited.
    [Show full text]
  • Cardiovascular Drugs and Therapies NITRATES COMPARISON CHART
    Cardiovascular Drugs and Therapies NITRATES COMPARISON CHART Isosorbide Generic Nitroglycerin Nitroglycerin Nitroglycerin Nitroglycerin Dinitrate Isosorbide Isosorbide Name Intravenous Patch Ointment Sublingual Sublingual Dinitrate 5-Mononitrate Trade Name TRIDIL, NITRODUR, NITROL NITROLINGUAL generics generics (for IMDUR, generics TRANSDERM- Pumpspray, immediate generics NITRO, RHO-NITRO release) MINITRAN, Pumpspray, SR: no longer TRINIPATCH NITROLINGUAL available Metered dose spray NITROSTAT sublingual tablet Dosage 100 mg/250 mL 0.2 mg/h 30 g/30 inches SL spray: SL tablet: 5mg Immediate SR tablet: Forms premixed bottle 0.4 mg/h ointment 0.4 mg/ dose release 60 mg SR - UHN 0.6 mg/h SL tablet: tablet: Note: 0.84 mL 0.8 mg/h 0.3 mg, 0.6 mg 10 mg *Non- alcohol per 100 mL 30 mg formulary at solution UHN 100 mcg/mL 200 mcg/mL 400 mcg/mL 10 mg/10 mL vial - UHN 50 mg/10 mL vial - UHN CARDIOVASCULAR PHARMACOTHERAPY HANDBOOK All contents copyright © University Health Network. All rights reserved Cardiovascular Drugs and Therapies NITRATES COMPARISON CHART Isosorbide Generic Nitroglycerin Nitroglycerin Nitroglycerin Nitroglycerin Dinitrate Isosorbide Isosorbide Name Intravenous Patch Ointment Sublingual Sublingual Dinitrate 5-Mononitrate Dosing Starting and 0.2 to 0.8 ½ inch to 1 inch SL spray: SL tablet: Immediate 60-240 mg SR Usual dose target doses mg/h once tid-qid; remove 0.4 mg prn; 5-10 mg q2-4h release: once daily range are determined daily. for 8-10 hours dose may be for prophylaxis 10-45 mg tid by clinical per 24-hour repeated after of acute angina on qid situation and 12-14 hour period; 5 minutes for schedule the number and patch-free response to interval e.g., ON 0600, total of 3 doses (e.g.
    [Show full text]
  • United States Patent 19 11) Patent Number: 5,665,766 Byrne Et Al
    US005665766A United States Patent 19 11) Patent Number: 5,665,766 Byrne et al. 45 Date of Patent: Sep. 9, 1997 54 ESTER OF AN ORGANIC NTRATE AND A FOREIGN PATENT DOCUMENTS SALCYTLATE 044.9426 10/1991 European Pat. Off.. 75 Inventors: William Byrne, Dublin; Andrew WO 92/O1668 2/1992 WIPO. Rynne, Clane, both of Ireland WO 92/16506 10/1992 WIPO . OTHER PUBLICATIONS 73 Assignee: Cal International Limited, Dublin, reland European HeartJournal, vol. 12. Sup.A. 1991, pp. 2-4 "Why Use a Nitrate in 1990'. 21 Appl. No.: 374,650 European Heart Journal, vol. 9, Supp. A 1988, pp. 45-49 22 PCT Filled: Jul. 26, 1993 "Mechanisms For The In Vivo Antiplatelet Effects of Isos orbide Dinitrate'. 86 PCT No.: PCT/E93/00040 Eur, J. Clin. Pharmacology, vol. 25, 1983, pp. 779-782 $371 Date: Jan. 30, 1995 "Pharmacological Internaction Between Nitroglycerin and Asprin After Acute and Chronic Aspirin Treatment of S 102(e) Date: Jan. 30, 1995 Healthy Subjects". 87 PCT Pub. No.: WO94/03421 J. Cardiovascular Pharmacology, vol. 5. No. 5, 1983, pp. 874-877 "Influence of Aspirin on the Hemodynamic Effects PCT Pub. Date: Feb. 17, 1994 of Sublingual Nitroglycerin". Foreign Application Priority Data AN 100 : 12587 Kim et al., "Pharmaceutical Studies on the 30 Estimation of Chloramphinzol with Antipyretics”. Yahihak Jul. 30, 1992 (E) Ireland ................................... 92.2474 Hoech, 27(3), 207-13. Abstract Only 1983. 51) Int. Cl. ............... A61K 31/34; CO7D 493/00 Primary Examiner-Marianne M. Cintins 52 U.S. Cl. ......................... 514/470; 514/475; 514/533; Assistant Examiner-Keith MacMillan 514/548; 549/464 Attorney, Agent, or Firm-Jacobson, Price, Holman & 58 Field of Search ....................................
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Rbfhss.2021.121.0562
    Abreu GA, Chaves EF, Neto JA, et al. Off-label use of drugs administered by enteral feeding tubes in an intensive care unit in Fortaleza, Brazil. Rev Bras Farm Hosp Serv Saude. 2021;12(1):0562. DOI: 10.30968/rbfhss.2021.121.0562. RBFHSSRevista Brasileira de Farmácia Hospitalar e Serviços de Saúde Original Paper Open Access Off-label use of drugs administered by enteral feeding tubes in an Intensive Care Unit in Fortaleza, Brazil Gabriela Araujo de ABREU1, Elana Figueiredo CHAVES1, José Alcântara NETO2, Lívia Porto MOREIRA1, Johann Vargas SILVA3, Andreína Fontenele TEIXEIRA, Marjorie Moreira GUEDES2, Milena Portela BESERRA2 1Programa de Residência Integrada Multiprofissional em Atenção Hospitalar à Saúde, Hospital Universitário Walter Cantídio, Universidade Federal do Ceará, Fortaleza, Brasil; 2Hospital Universitário Walter Cantídio, Fortaleza, Brasil; 3Programa de Residência Médica em Terapia Intensiva, Hospital Universitário Walter Cantídio, Universidade Federal do Ceará, Fortaleza, Brasil Corresponding author: Abreu GA, [email protected] Submitted: 13-01-2021 Resubmitted: 07-03-2021 Accepted: 07-03-2021 Peer review: blind reviewer and Juliana Miranda Ferreira Abstract Objective: To analyze the prescription profile of drugs administered through enteral feeding tubes in an adult intensive care unit and gather recommendations for their safe administration. Methods: This is a descriptive and cross-sectional study conducted with adult critical clinical patients of a university hospital in Fortaleza-Ceará from March to May 2018. We performed analyses of patients’ medical records and prescriptions regarding drugs, pharmaceutical presentations and the possibility of administration through enteral tubes. Results: 489 prescriptions containing 1914 items were evaluated, from which 16.6% (n = 318) through tubes.
    [Show full text]
  • The Availability of Organic Nitrates from Intravenous Administration Systems
    THE AVAILABILITY OF ORGANIC NITRATES FROM INTRAVENOUS ADMINISTRATION SYSTEMS by Paul Adrian Cossum B.Sc., M.P.S. submitted in partial fulfilment of the requirements for the degree of Master of Pharmacy UNIVERSITY OF TASMANIA - HOBART JUNE 1981 SUMMARY Nitroglycerin aind isosorbide dinitrate are two drugs which are infused intravenously during the treatment of ischaemic heart disease. The availability of these two drugs in solutions infused from plastic infusion bags or glass infusion bottles through plastic giving sets has been investigated. During simulated infusions the concentration of nitroglycerin and isosorbide dinitrate appearing in the effluent of the • giving set tubing was found to be much less than the concentration of the drug solution initially contained in the plastic infusion bag or glass infusion bottle. It was found that each component of the plastic infusion equipment sorbed the drugs to a significant extent and that the rate of disappearance of drugs from solutions stored in each component was in the rank order: giving set tubing > giving set burette > plastic infusion bag. There was no significant loss of either drug from solutions stored in glass bottles. The influence of formulation factors and storage conditions on the sorption of nitroglycerin, isosorbide dinitrate and another organic nitrate compound., ethylene glycol dinitrate, by plastic infusion equipment was studied. The extent of loss during simulated infusions was also found to be dependent on flow rate of drug solution through the giving set. The sorption of nitroglycerin and isosorbide dinitrate has clinical and pharmacokinetic significance. Losses of nitroglycerin and isosorbide dinitrate associated with their infusion through plastic Lnfusion equipment were minimised by infusing drug solutions from a glass syringe through high density polyethylene tubing.
    [Show full text]
  • Use of Sildenafil in Patients with Cardiovascular Disease
    Arq Bras Cardiol GuimarãesReview et al volume 73, (nº6), 1999 Sildenafil in patients with cardiovascular disease Use of Sildenafil in Patients with Cardiovascular Disease Armênio Costa Guimarães, Marcus Vinícius Bolívar Malachias, Otávio Rizzi Coelho, Emílio Cesar Zilli, Rafael Leite Luna Introduction of phosphodiesterase inhibitors. The erectile action of sildenafil combines increase in arterial flow with reduction Erectile dysfunction, formerly called impotence, is the in the venous flow of cavernous body of penis. Sildenafil inability of the male to achieve or maintain penile erection and leads to relaxation of smooth muscle of penile arteries and thus engage in coitus1. It is common among patients with trabeculae surrounding the sinusoidal spaces, resulting in cardiovascular diseases or their risk factors. This dysfunc- a greater engorgement of cavernous body. The trabeculae tion occurs mainly among individuals with coronary artery of engorged sinusoidal spaces compress the penile disease, after episodes of acute ischemic syndrome, hyper- venules against the tunica albuginea, reducing venous tensive patients underpharmacologic treatment, and among flow, contributing to maintenance of engorgement of patients with heart failure. In approximately 85% of these ca- cavernous body8. Relaxation of this smooth muscle ses, the fear of a cardiac event during coitus constitutes an results from a decrease in intracellular calcium mediated important factor for erectile dysfunction 2-4. by accumulation of the second messenger, the cyclic Discovery of sildenafil citrate has represented a great de- guanosine monophosphate (cGMP), whose production velopment in the treatment of erectile dysfunction; it may results from activation of guanyl cyclase by nitric oxide benefit, among many others, those patients with cardiovascu- produced by the stimulus of endothelial cells generated lar diseases or with their risk factors 5.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin Et Al
    USOO9636405B2 (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin et al. (45) Date of Patent: May 2, 2017 (54) FOAMABLE VEHICLE AND (56) References Cited PHARMACEUTICAL COMPOSITIONS U.S. PATENT DOCUMENTS THEREOF M (71) Applicant: Foamix Pharmaceuticals Ltd., 1,159,250 A 1 1/1915 Moulton Rehovot (IL) 1,666,684 A 4, 1928 Carstens 1924,972 A 8, 1933 Beckert (72) Inventors: Dov Tamarkin, Maccabim (IL); Doron 2,085,733. A T. 1937 Bird Friedman, Karmei Yosef (IL); Meir 33 A 1683 Sk Eini, Ness Ziona (IL); Alex Besonov, 2,586.287- 4 A 2/1952 AppersonO Rehovot (IL) 2,617,754. A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (73) Assignee: EMY PHARMACEUTICALs 2.968,628 A 1/1961 Reed ... Rehovot (IL) 3,004,894. A 10/1961 Johnson et al. (*) Notice: Subject to any disclaimer, the term of this 3,062,715. A 1 1/1962 Reese et al. tent is extended or adiusted under 35 3,067,784. A 12/1962 Gorman pa 3,092.255. A 6/1963 Hohman U.S.C. 154(b) by 37 days. 3,092,555 A 6/1963 Horn 3,141,821 A 7, 1964 Compeau (21) Appl. No.: 13/793,893 3,142,420 A 7/1964 Gawthrop (22) Filed: Mar. 11, 2013 3,144,386 A 8/1964 Brightenback O O 3,149,543 A 9/1964 Naab (65) Prior Publication Data 3,154,075 A 10, 1964 Weckesser US 2013/0189193 A1 Jul 25, 2013 3,178,352.
    [Show full text]